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Abstract More than half a century of research on peroxi-
somes has revealed unique features of this ubiquitous
subcellular organelle, which have often been in disagree-
ment with existing dogmas in cell biology. About 50 perox-
isomal enzymes have so far been identiWed, which
contribute to several crucial metabolic processes such as
-oxidation of fatty acids, biosynthesis of ether phospholip-
ids and metabolism of reactive oxygen species, and render
peroxisomes indispensable for human health and develop-
ment. It became obvious that peroxisomes are highly
dynamic organelles that rapidly assemble, multiply and
degrade in response to metabolic needs. However, many
aspects of peroxisome biology are still mysterious. This
review addresses recent exciting discoveries on the biogen-
esis, formation and degradation of peroxisomes, on peroxi-
somal dynamics and division, as well as on the interaction
and cross talk of peroxisomes with other subcellular com-
partments. Furthermore, recent advances on the role of per-
oxisomes in medicine and in the identiWcation of novel
peroxisomal proteins are discussed.
Keywords Peroxisomes · Mitochondria · Organelle 
dynamics · Biogenesis · Organelle cross talk · Dynamin · 
Disease · Pexophagy · Fatty liver disease · 
NeuroinXammation
Abbreviations
ALDP Adrenoleukodystrophy protein
CNS Central nervous system
ER Endoplasmic reticulum
FLD Fatty liver disease
PBD Peroxisome biogenesis disorder
PEX Peroxin
PMP Peroxisomal membrane protein
PPAR Peroxisome proliferator activated receptor
PTS Peroxisomal targeting signal
ROS Reactive oxygen species
VLCFA Very-long-chain fatty acids
Introduction: early milestones in peroxisome research
Peroxisomes (originally called microbodies) were discov-
ered in 1954 using electron microscopy in mouse kidney
(Rhodin 1954), 4 years before the Wrst issue of this Journal
(which in 1995 became Histochemistry and Cell Biology)
was published. Since then the “Cinderella” among the sub-
cellular organelles, which was once considered to be a “fos-
sil organelle” and had been regarded as the cell’s “garbage
pail”, has experienced a remarkable rise and turned into a
dynamic and metabolically active cellular compartment
essential for human health and development. De Duve and
Baudhuin (1966) were the Wrst who isolated peroxisomes
from rat liver, and their biochemical studies led to the dis-
covery of the colocalization of several H2O2-producing oxi-
dases as well as catalase, an H2O2-degrading enzyme, in the
matrix of peroxisomes (Fig. 1). On the basis of these Wnd-
ings, De Duve proposed the functional term “peroxisome”,
which gradually replaced the former morphological desig-
nation, “microbody”, coined by Rhodin (Rhodin 1954). A
speciWc cytochemical staining for peroxisomes in light and
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electron microscopy became available with the introduction
of the alkaline 3, 3-diaminobenzidine (DAB) reaction for
catalase (Fahimi 1968,  1969; NovikoV and GoldWscher
1969) (Fig. 2). Subsequent morphological studies exploit-
ing this cytochemical procedure revealed that peroxisomes,
such as mitochondria, are ubiquitous eukaryotic organelles
(Hruban et al. 1972). They disappear during the develop-
ment of red blood cells and sperms (Luers et al. 2006), and
appear to be absent in the Apicomplexa phylum and in ami-
tochondriate parasites (Schluter et al. 2006) (see “Peroxi-
somes in silico”). In contrast to mitochondria, peroxisomes
(0.1–1 m in diameter) are devoid of DNA, and have a sin-
gle-limiting membrane surrounding a Wne granular matrix,
which may contain crystalline inclusions of matrix
enzymes (Fig. 2). Pharmacological studies with hypolipi-
demic drugs and plasticizers (so-called peroxisome pro-
liferators) led to the observation that peroxisomes can
remarkably increase in number and size, especially in the
livers of rodents (Hess et al. 1965; Svoboda and AzarnoV
1966; Fahimi et al. 1982; Reddy and Lalwani 1983). Such a
“peroxisome proliferation” is often accompanied by an
increase in the synthesis of peroxisomal enzymes, and can
result in the formation of hepatic tumors, mainly in rodents
(Reddy et al. 1980, 1982; Moody et al. 1991). This selec-
tive induction of peroxisomal genes by those compounds is
mediated by peroxisome proliferator activated receptor-
(PPAR), which belongs to the family of nuclear transcrip-
tion factors (Issemann and Green 1990) and acts as hetero-
dimeric partner with retinoid X receptor by binding to the
peroxisome proliferator response elements (PPREs). On the
basis of similar pharmacological studies, a fatty acid -oxi-
dation system in peroxisomes was discovered (Fig. 1),
which coexists and cooperates with the mitochondrial fatty
acid -oxidation system in animal cells (Lazarow and De
Duve  1976; Wanders 2000). Interestingly, in plant cells
(Cooper and Beevers 1969) and in eukaryotic microorgan-
isms, peroxisomes are the only site of -oxidation (Poirier
et al. 2006) which renders them essential for the utilization
of fat in these organisms. Their important role in lipid
metabolism as well as in health and disease became obvi-
ous in the 1980s, when the major function of peroxisomes
in the -oxidation of very-long-chain fatty acids (VLCFA)
and in the biosynthesis of ether glycerolipids (plasmalo-
gens) was discovered (Hajra et al. 1979; Brown et al. 1982)
(Fig. 1). Their absence in Zellweger syndrome, the Wrst
genetic neurodegenerative peroxisomal disorder, was
reported by GoldWscher et al. (1973) and was later linked to
abnormalities in lipid metabolism (Heymans et al. 1983).
Since then, ongoing research on the biogenesis of peroxi-
somes and their metabolic functions has greatly improved
our knowledge about their crucial role in several inherited
disorders, which are often not compatible with life or nor-
mal development (Weller et al. 2003; Wanders and Water-
ham 2005; Steinberg et al. 2006; Wanders and Waterham
2006a) and in other pathophysiological conditions (Table 1
and “Mysterious protection: some recent observations on
the relevance of peroxisomes in medicine”).
About 85 genes in Homo sapiens and 61 genes in Saccha-
romyces cerevisiae have been identiWed, which encode for
peroxisomal proteins. Many of these proteins are metabolic
enzymes (about 50 in mammalian peroxisomes), whereas
some 32 proteins/genes, so-called peroxins (Pex), have been
discovered, which are required for the biogenesis and mainte-
nance of functional peroxisomes (32 in yeast, with approxi-
mately 20 mammalian and 23 plant homologs) (Kiel et al.
2006; Platta and Erdmann 2007a) (Fig. 3). Besides their
essential catabolic (oxidation of pipecolic, phytanic and very-
long-chain fatty acids) and anabolic (synthesis of plasmalo-
gens, bile acids and cholesterol) functions in lipid metabolism
(Fig. 1), peroxisomes play a key role in free radical detoxiWca-
tion, diVerentiation, development and morphogenesis from
human to yeast. Although many peroxisomal enzymes and
metabolic pathways have been well characterized (Table 2),
Fig. 1 The major metabolic pathways in peroxisomes of the mamma-
lian liver. The very-long-chain fatty acids (VLCFA) are transported by
membrane proteins (e.g., the ABC transporter proteins PMP70 or AL-
DP) (see Table 1) into the matrix, where they are oxidized by the lipid
-oxidation enzymes. Multiple acyl-CoA oxidases and thiolases, as
well as two distinct multifunctional (hydratase/3-hydroxyacyl-CoA
dehydrogenase) enzymes coexist in peroxisomes (Poirier et al. 2006).
The products of the -oxidation can either serve as substrates for the
biosynthesis of ether glycerolipids, cholesterol and bile acids or may
exit the peroxisome for further oxidation in mitochondria (MITO). Per-
oxisomal -oxidation and the activity of other peroxisomal oxidases
result in the production of hydrogen peroxide, which is decomposed by
catalase. Asterisks there are separate enzymes for bile acid intermedi-
ates, sER smooth endoplasmic reticulum, ALDP adrenoleukodystro-
phy proteinHistochem Cell Biol (2008) 129:421–440 423
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research on peroxisomal metabolism is still continuing (van
den Bosch et al. 1992; Wanders and Waterham 2006b). Note-
worthy, peroxisomes in plants, yeasts and protozoa generally
possess a far wider spectrum of activities than in vertebrates
(e.g. penicillin biosynthesis in Wlamentous fungi, glyoxylate
cycle, photorespiration, plant hormone biosynthesis/metabo-
lism, and pathogen interaction in plants) (van der Klei et al.
2006; Kunze et al. 2006; Reumann and Weber 2006).
Fig. 2 a Cytochemical localiza-
tion of catalase in rat hepatic 
peroxisomes stained with the 
alkaline diamino-benzidine 
technique (Fahimi 1969). Note 
the uniform staining of the per-
oxisome matrix. MagniWcation, 
£28,600. b Cytochemical local-
ization of urate oxidase in rat liv-
er using the cerium method 
(Angermuller and Fahimi 1986). 
Note the dark staining of the 
crystalline core (arrowheads). 
MagniWcation, £50,400. c 
Immunocytochemical localiza-
tion of catalase in rat liver using 
the protein A-gold technique 
(Fahimi et al. 1996). Note the di-
Vuse labelling of the matrix with 
gold particles and the sparing of 
the core region. MagniWcation, 
£72,000. d Immunocytochemi-
cal localization of urate oxidase 
in rat liver using the protein 
A-gold technique (Völkl et al. 
1988). Note the exclusive label-
ling of the core with gold parti-
cles (arrowheads). 
MagniWcation, £61,600. e An 
autophagic vacuole in rat liver 
from an animal treated with the 
peroxisome proliferator bezaW-
brate. Note the presence of a per-
oxisome, stained for catalase 
with the diamino-benzidine 
reaction, in the autophagic vacu-
ole. MagniWcation, £38,000. 
PO peroxisome, MITO mitoc-
hondrium424 Histochem Cell Biol (2008) 129:421–440
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Table 1 Disorders related to peroxisomes
Peroxisome biogenesis disorders
Peroxisomal disease Onset Defect Genes involved
Zellweger syndrome (ZS) (neonatal hypotonia, 
craniofacial dysmorphy, hepatomegaly, renal cysts, 
adrenal atrophy, neurological abnormalities, such as 
dys- or demyelination and neuronal migration defects)
Prenatal, lethal within 1 year of age Peroxisome 
biogenesis
DiVerent 
PEX genes
Neonatal ALD (NALD) 1 year, lethal between 1 and 5 years of age Peroxisome 
biogenesis
DiVerent 
PEX genes
Infantile Refsum’s disease (IRD) <1 year, lethal after 10–30 years of age; 
older patients are known
Peroxisome 
biogenesis
DiVerent 
PEX genes
Rhizomelic chondrodysplasia 
punctata type 1 (RCDP type 1)
Prenatal, lethal within 1 year or the 
Wrst decade; older patients are known 
PTS2 matrix 
protein import
PEX7
Single enzyme deWciencies
Peroxisomal disease Onset Enzyme and pathway aVected Genes involved
X-linked adrenoleukodystrophy (X-ALD) 
(accumulation of VLCFA, progressive 
demyelination/neurodegeneration in the 
CNS, adrenal insuYciency) “Lorenzos Oil”
3–10 years for childhood 
ALD, 20–40 years for 
adult AMN, lethal
ALDP, -oxidation of VLCFA ABCD1
Contiguous ABCD1/DX1357E deletion syndrome Prenatal ABC transporters, -oxidation ABCD1, BCAP31
Pseudo-neonatal ALD (acyl-CoA oxidase deWciency) Prenatal, lethal within 
the Wrst decade
ACOX1, -oxidation ACOX1
D-bifunctional protein deWciency/multifunctional 
protein 2 deWciency
Prenatal DBP, -oxidation HSD17B4
Adult-onset sensory motor neuropathy 
(-methylacyl-CoA racemase deWciency)
Childhood and adult AMACR, -oxidation of branched 
chain fatty acids, including pristanic 
acid and bile acid intermediates; 
-oxidation of VLCFA is normal
AMACR
Refsum’s disease (phytanol-CoA 
hydroxylase deWciency)
10–20 years PHYH/PAHX, -oxidation PHYH/PAHX
Rhizomelic chondrodysplasia punctata type 2 
(DHAPAT deWciency)
<1 year DHAPAT, ether 
phospho-lipid synthesis
GNPAT
Rhizomelic chondrodysplasia punctata type 3 
(alkyl-DHAP synthase deWciency)
Prenatal ADHAPS, -oxidation AGPS
Sterol carrier protein X deWciency 1 patient SCPx -oxidation of branched 
chain fatty acids only
SCP2
Hyperoxaluria type 1 (alanine glyoxylate 
aminotransferase deWciency)
<5 years, lethal AGT, glyoxylate detoxiWcation AGXT
Acatalasaemia Adult CAT, H2O2-metabolism CAT
Potential other single enzyme deWciencies
(Peroxisomal) disease Onset Enzyme and pathway aVected Genes involved
Mental retardation X-linked 63, MRX63 ? Long-chain acyl-CoA synthetase 4, 
fatty acid activation
FACL4
Malonic aciduria (MCD localizes to 
mitochondria, the cytosol and peroxisomes)
Early childhood (5 years) Malonyl-CoA decarboxylase, fatty acid 
oxidation, but no peroxisomal 
abnormalities detected so far
MLYCD
Sjogren–Larsson syndrome At birth or soon after Aldehyde dehydrogenase, phytanic 
acid metabolism/microsomal 
detoxiWcation system
ALDH3A2
Glutaryl-CoA oxidase deWciency 
(glutaric aciduria type 3)
1 year Glutaryl-CoA oxidase ?
Amyotrophic lateral sclerosis (ALS1) Variable (19–46 years) Cu/Zn-superoxide dismutase 1 SOD1Histochem Cell Biol (2008) 129:421–440 425
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The biogenesis of peroxisomes
Protein import into peroxisomes: the mysterious membrane 
pore
Peroxisomes do not contain DNA or protein translation
machinery, and all their proteins are encoded by nuclear
genes. Majority of the peroxisomal proteins are synthesized
on free polyribosomes in the cytoplasm and are imported
post-translationally (Lazarow and Fujiki 1985) (Fig. 3). A
major breakthrough in the elucidation of the mechanism of
protein import into peroxisomes was the identiWcation of
the Wrst peroxisomal targeting signal (PTS1) at the C-termi-
nus of luciferase of the WreXy Photinus pyralis (Keller et al.
1987; Gould et al. 1987). Luciferase actually localizes to
peroxisomes in cells of the lantern organ of the WreXy
where it catalyzes the light-producing bioluminescent reac-
tion. Today, we know that majority of the peroxisomal
matrix proteins contain a C-terminal PTS1, and very few an
N-terminal PTS2. It also became clear that the import into
peroxisomes is a unique process, which diVers substantially
from the import mechanisms into the ER, mitochondria or
chloroplasts. The peroxisomes import fully folded, co-fac-
tor bound and even oligomeric proteins by shuttling recep-
tors (Leon et al. 2006). The PTS1- or PTS2-containing
matrix proteins are recognized by soluble receptors (PTS1
by Pex5p, a tetra-tricopeptide repeat (TPR) domain protein,
PTS2 by Pex7p, a WD40 domain protein, and its corecep-
tors) in the cytosol, which guide them to a docking site at
the peroxisomal membrane (Fig. 3). After translocation of
the receptor–cargo complex to the luminal side of the per-
oxisomal membrane, the cargo is released and the receptors
shuttle back to the cytosol. Whereas the components of the
import machinery (the importomer complex; composed of
the docking and RING subcomplexes which in yeast are
bridged by Pex8p or Pex3p) (Fig. 3) and their interactions
have been quite well studied (Rayapuram and Subramani
2006; Platta and Erdmann 2007b), the mechanism of trans-
location of folded proteins across the membrane and the
cargo release still remain mysterious (Gould and Collins
2002). A stable import channel or membrane pore, like in
the nucleus, is missing in the peroxisomal membrane. As an
alternative to a pore, a pinocytosis-like mechanism has also
been proposed (McNew and Goodman 1996). Recently, the
existence of a “transient pore” has been postulated, which
might be dynamically formed by the import receptors them-
selves (Erdmann and Schliebs 2005). In this respect, it is
also noteworthy that very little is known about the mem-
brane channels and transporters of peroxisomes, which are
involved in membrane permeability and solute transfer of
Table 1 continued
Mevalonate kinase deWciency is no longer considered to be a peroxisomal disorder (Hogenboom et al. 2004)
Peroxisomes are essential for human health and normal development. A defect in a peroxisomal gene can lead to a single enzyme deWciency which
might aVect one speciWc peroxisomal function or metabolic pathway. In peroxisome biogenesis disorders (PBDs) the aVected protein is a peroxin
(involved in the biogenesis and maintenance of peroxisomes). In PBDs several or all peroxisomal functions can be aVected, and peroxisomes can
be completely absent. As many peroxins are involved in matrix protein import (targeting, docking, translocation and receptor recycling) (see Intro-
duction and Fig. 3), a lack of matrix protein import is often observed, whereas the synthesis of peroxisomal membranes and import of PMPs is
unaVected. Loss of matrix protein import results in the formation of “empty”, non-functional peroxisomal membranes, so-called “ghosts”, which
cannot fully develop and mature. The peroxisomal matrix proteins remain in the cytosol, where they cannot function or are degraded. An accumu-
lation of peroxisomal substrates (e.g., VLCFA, plant-derived pristanic and phytanic acids, bile acid intermediates, and pipecolic acid, an interme-
diary in lysine metabolism) occurs, which can only be handled by peroxisomes, and are toxic for the cell/organism. Furthermore, a shortage of end
products of peroxisomal metabolism (e.g., ether glycerolipids/plasmalogens, which comprise more than 80% of the phospholipid content of white
matter in the brain) is observed. Organs aVected in most peroxisomal disorders include brain, spinal cord, or peripheral nerves, eye, ear, liver, kid-
ney, adrenal cortex, Leydig cells in testis, skeletal system, and in some instances cardiovascular system, thymus, and pancreas. Centres for the
study of peroxisomal diseases are the Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands, and
the Kennedy Krieger Institute, Baltimore, MD/USA. Links: The Myelin Project (http://www.myelin.org/), OMIM (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=omim)
Potential other single enzyme deWciencies
Xanthinuria (XDH localizes to peroxisomes and the cytosol) Childhood 
(1–20 years)
Xanthine dehydrogenase, purine metabolism XDH
Mulibrey nanism (muscle–liver–brain–eye nanism) Perinatal TRIM domain-dependent E3 ubiquitin 
ligase, unknown
TRIM37
Glomerulosclerosis (there is evidence that Mpv17p is 
mitochondrial and not peroxisomal; Spinazzola et al. 2006)
Only in mice Mpv17 protein, PXMP 2/4 family proteins MPV17
Combined mitochondrial peroxisomal deWciencies
Disease Onset Enzyme and pathway aVected Genes involved
DLP1 deWciency (Waterham et al. 2007) Prenatal, lethal Dynamin-like GTPase, Fission defect 
of both mitochondria and peroxisomes
DNM1L426 Histochem Cell Biol (2008) 129:421–440
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metabolites (Antonenkov and Hiltunen 2006; Visser et al.
2007).
It has also been shown that Pex5p can be ubiquitinated
(Erdmann and Schliebs 2005; Kragt et al. 2005b; Thoms
and Erdmann 2006). Monoubiquitination of Pex5p appears
to be a prerequisite for its dislocation from the peroxisomal
membrane, and depends on the E2 enzyme Pex4p (Platta
and Erdmann 2007a; Carvalho et al. 2007). Its function has
been a mystery for over a decade; however, respective E3
enzymes are still elusive (the RING Wnger proteins Pex2p,
Pex10p and Pex12p might be good candidates for the miss-
ing ubiquitin ligases). The membrane detachment/recycling
of Pex5p is ATP dependent (but not the binding and trans-
location of Pex5p itself), and depends on AAA-ATPases
Pex1p and Pex6p (Fig. 3). Polyubiquitination of Pex5p is
believed to be part of a quality control process, which
results in proteasomal degradation of dysfunctional recep-
tor molecules (Platta and Erdmann 2007a). Noteworthy,
these processes show a striking analogy to ERAD, the ER-
associated degradation process (see also “Peroxisomes in
silico”).
Interestingly, there is experimental evidence that manipu-
lation of the peroxisomal import of catalase has an inXuence
on aging. The alteration of the PTS1 of catalase to a more
eVective serine–lysine–leucine (SKL) sequence repolarized
mitochondria and reduced cellular hydrogen peroxide levels
and the number of senescent cells in a population (Terlecky
et al. 2006; Koepke et al. 2007). Furthermore, targeting of
catalase to mitochondria in transgenic mice has demon-
strated to increase murine life span (Schriner et al. 2005).
The targeting and insertion of peroxisomal membrane
proteins (PMPs) require other components than those
involved in peroxisomal matrix import and is less well
understood (Heiland and Erdmann 2005; Van Ael and
Fransen 2006; Fujiki et al. 2006). Those PMPs, which are
synthesized on free ribosomes in the cytosol, contain inter-
nal membrane targeting sequences (mPTS), which com-
prise a Pex19p-binding site and a membrane-anchoring
sequence (either a transmembrane domain or a protein
binding site) (Van Ael and Fransen 2006). Pex19p is sug-
gested to function as a cycling receptor/chaperone, which
binds the PMPs in the cytosol and is then recruited to the
peroxisome by the membrane receptor Pex3p (Fujiki et al.
2006) (Fig. 3). In mammals, Pex16p is also required, which
might function as a tethering factor for Pex3p, or as part of
the putative membrane-insertion machinery. A loss of
Pex3p, Pex16p, or Pex19p results in the absence of
detectable peroxisomes/peroxisomal membranes, whereas
reintroduction surprisingly leads to a de novo formation of
peroxisomes from the ER (see below). Some PMPs (e.g.,
Pex3p and Pex16p) are supposed to be targeted indirectly to
peroxisomes via the ER by an as yet unknown mechanism
(see below).
Fig. 3 Schematic overview of peroxins and other poteins at the perox-
isomal membrane. Cargo proteins containing the peroxisomal target-
ing signals PTS1 or PTS2 bind to the corresponding receptors Pex5p
or Pex7p and form receptor-cargo complexes. The Pex7p–cargo com-
plex requires accessory factors for import (Pex5pL, a long isoform of
Pex5p, in mammals and plants, Pex18p and Pex21p in S. cerevisiae,
Pex20p in Neurospora crassa, Yarrowia lipolytica, and Hansenula
polymorpha). The receptor–cargo complex in yeast and mammals
interacts with a docking site (Pex13p, Pex14p and Pex 17p). It is un-
clear whether the receptors translocate fully into the matrix (“extended
shuttle hypothesis”) or remain associated with the translocation com-
plex (“shuttle hypothesis”). The docking and RING complexes (Pex2p,
Pex10p, Pex12p) involved in translocation in yeast and mammals are
bridged by Pex8p in S. cerevisiae. Recycling of cargo-released Pex5p
to the cytosol requires Pex4p, an ubiquitin-conjugating enzyme that is
bound to Pex22p, and the AAA-ATPases Pex1p and Pex6p. Pex6p
binds to Pex15p in S. cerevisiae or to Pex26p in humans. The DnaJ-like
protein Djp1p assists in matrix protein import. Membrane assembly
and insertion of peroxisomal membrane proteins (PMPs) (containing
an mPTS) depends on Pex19p, Pex3p and Pex16p. Pex19p functions as
a cycling receptor/chaperone, which binds the PMPs in the cytosol and
interacts with Pex3p at the peroxisomal membrane. Pex11p, Pex11p
and Pex11p are the only peroxins known to be involved in the regula-
tion of peroxisome size and number (proliferation) in mammals. In
Y. lipolytica (Pex23p, and Pex24p) and S. cerevisiae (Pex25p, Pex27p-
Pex32p) several other peroxins have been identiWed which inXuence
the size and number or organization of peroxisomes. The division of
peroxisomes is mediated by Fis1p and dynamin-like GTPases (DLP1/
DRP1 in mammals, DRP3A in plants, Vps1p, Dnm1p in S. cerevisiae).
Fis1p is the membrane receptor for DLP1 on peroxisomes (and mito-
chondria). Inp1p and Inp2p are involved in the inheritance and motility
of peroxisomes in S. cerevisiae and Y. lipolytica. Inp2p is the mem-
brane receptor for the type V myosin motor Myo2p on peroxisomes,
which drives peroxisomes along actin Wlaments. The GTPase Rho1p
binds to Pex25p and is involved in the recruitment of actin to peroxi-
somes in S. cerevisiae. Mammalian peroxisomes move along microtu-
bules and bind dynein and kinesin motors by a yet unknown
mechanism. Other membrane proteins are members of the PXMP34
and PXMP2/4 families, as well as the four ABC transporter proteins in
mammals. Other PMPs are PMP22, PMP47, and the recently identiWed
PMP52, as well as Mosc2 and ATAD1, an AAA-ATPase. Proteins
with a dual localization to both peroxisomes and mitochondria are
marked with asterisk. The ORF of YlPEX9 was misidentiWed; it corre-
sponds to HsPEX26. ALD adrenoleukodystrophy protein, ALDR ALD-
related proteinHistochem Cell Biol (2008) 129:421–440 427
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Mysterious formation: growth and division, de novo 
formation, or both?
Since their discovery in 1954, there has been much specula-
tion about the formation of peroxisomes. It was suggested
that peroxisomes were precursors of mitochondria (Bern-
hard and Rouiller 1956), that they could arise from the
Golgi complex (Rouiller and Jezequel 1963) or were spe-
cialized forms of lysosomes (NovikoV and Essner 1960).
Whereas those concepts were abandoned with improve-
ments in cytochemical methods, it was also proposed that
peroxisomes formed from terminal cisternae of the ER
(NovikoV and Shin 1964). However, the discovery of the
synthesis of peroxisomal proteins on free polyribosomes in
the cytoplasm (Goldman and Blobel 1978), their post-trans-
lational transport into peroxisomes, and the observations of
interconnections between peroxisomes, led to the proposal
of the “growth and division” model of peroxisome biogene-
sis with formation out of pre-existing organelles (Lazarow
and Fujiki 1985). Recent discoveries have again challenged
this classical view. The peroxins Pex3p, Pex19p and
Pex16p are required to maintain the peroxisomal membrane
(South and Gould 1999; Hettema et al. 2000; Heiland and
Erdmann  2005), and their loss of function leads to the
absence of peroxisomal membranes and thus, peroxisomes.
Transexpression of Pex3, Pex19 or Pex16 and re-introduc-
tion of the missing genes has now been demonstrated to
restore peroxisome formation in yeast and mammals, and
lead to the postulation of a de novo synthesis of peroxi-
somes (Matsuzono et al. 1999; South and Gould 1999;
Muntau et al. 2000; Titorenko and Rachubinski 2001;
Faber et al. 2002; Geuze et al. 2003; Hoepfner et al. 2005;
Kragt et al. 2005a; Haan et al. 2006; Kim et al. 2006).
Pex3p and Pex19p have been observed to initially localize
to the ER before maturing into import-competent peroxi-
somes (Hoepfner et al. 2005; Tam et al. 2005; Haan et al.
2006), indicating that the ER/nuclear envelope is the source
of the newly synthesized membrane and organelle.
However, peroxisomes have also been reported to divide,
and recently proteins have been identiWed in yeast, mamma-
lian and plant cells, which play a role in peroxisomal Wssion.
Among them are dynamin-like GTPases (DLPs) with mech-
anochemical properties (yeast Dnm1p and Vps1p, mamma-
lian DLP1/Drp1, plant DRP3A), Fis1p, a membrane adaptor
for DLPs, and Pex11 proteins (for recent reviews see Sch-
rader and Fahimi 2006; Fagarasanu et al. 2007) (Fig. 3).
Morphological observations show that growth and division
of peroxisomes in mammalian cells is a multistep process
including peroxisome elongation, constriction, and Wnal
Wssion (Koch et al. 2003, 2004, 2005) (Figs. 4, 5). Peroxi-
somes tend to have a characteristic, segmented, “beads on a
string”-like appearance before they divide and distribute
(Schrader et al. 1996), or when DLPs are non-functional
(Hoepfner et al. 2001; Koch et al. 2003, 2004; Tanaka et al.
2006; Waterham et al. 2007) (Fig. 4). Pex11 proteins are
implicated early on in the elongation step of peroxisomes,
whereas Fis1p and DLPs are required for the Wnal Wssion
step (Thoms and Erdmann 2005; Schrader and Fahimi 2006;
Fagarasanu et al. 2007; Kobayashi et al. 2007) (Fig. 5). Per-
oxisomal constriction can proceed independently of DLP1
(Koch et al. 2004), but the molecular mechanism is so far
largely unknown. Interestingly, Fis1p and DLP1 (Dnm1p,
DRP3A) are also involved in mitochondrial Wssion (Hoo-
pins et al. 2007), and are shared by both organelles (Sch-
rader 2006). These Wndings indicate that peroxisomes and
mitochondria share some basic characteristics and are much
closer than previously assumed, thus underlining the tight
cooperation and cross talk between both organelles
Table 2 Metabolic functions of 
peroxisomes Peroxide metabolism (catalase and H2O2-generating oxidases), ROS/NOS metabolism
Lipid biosynthesis (ether phospholipids/plasmalogens, bile acids, cholesterol 
and dolichol, fatty acid elongation)
Fatty acid -oxidation (very-long-chain fatty acids, dicarboxylic acids, branched 
chain fatty acids, unsaturated fatty acids, arachidonic acid metabolism, 
and xenobiotic compounds)
Fatty acid -oxidation (phytanic acid, xenobiotic compounds)
Long/very-long fatty acid activation
Regulation of acyl-CoA/CoA ratio
Protein/amino acid metabolism (biosynthesis of cysteine and sulfur assimilation, 
D-amino acid degradation, L-lysine metabolism, degradation of polyamines, 
proteases, transaminases)
Catabolism of purines
Glyoxylate and dicarboxylate metabolism
Hexose monophosphate pathway
Glycerol synthesis
Nicotinate and nicotinamide metabolism
Retinoid metabolism428 Histochem Cell Biol (2008) 129:421–440
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(Schrader and Yoon 2007) (Figs. 4,  5; and “Peroxisomes
and mass spectrometry”). Similar to mitochondria, peroxi-
somal morphology and dynamics might inXuence peroxi-
somal functions as well as developmental and physiological
processes. Interestingly, a lethal defect in peroxisomal and
mitochondrial Wssion, which appears to be based on a point
mutation in the DLP1 gene, has recently been described
(Waterham et al. 2007). These Wndings might point to a new
class of diseases characterized by defects in peroxisomes
and mitochondria (Table 1).
The physiological signiWcance of the mechanism of de
novo formation in comparison to the classical pathway of
growth and division is still controversially discussed
(Lazarow 2003; Kunau 2005; Haan et al. 2006; Mullen and
Trelease 2006; Tabak et al. 2006). In order to investigate to
what extent these pathways of peroxisome formation
Fig. 4 Fluorescence microscopy of peroxisomes (a, b) and mitochon-
dria (a) in human hepatoma cells. Cells were stained with antibodies to
the peroxisomal membrane protein PMP70 (a, green; b) and to mito-
chondrial manganese superoxide dismutase (MnSOD) (a, red). Peroxi-
somes exhibit spherical, rod-shaped and elongated, tubular
morphologies, whereas mitochondria form an interconnected tubular
network. During division peroxisomes appear like “beads on a string”
(arrow) (Schrader et al. 1996). Boxed region shows higher magniWca-
tion view. (b) Peroxisome morphology after silencing of DLP1 by siR-
NA. Note the highly elongated but constricted appearance of
peroxisomes defective in Wnal membrane Wssion (arrows). The forma-
tion of spherical peroxisomes by division is completely inhibited.
N nucleus. Scale bars, 10 m (a, b)
Fig. 5 Model of peroxisome dynamics and interactions in mammalian
cells. The majority of the peroxisomal matrix and membrane proteins
(Class I PMPs) are synthesized on free polyribosomes in the cytosol
and are post-translationally imported into pre-existing peroxisomes.
Some membrane proteins (Class II PMPs, early peroxins, for example,
Pex3p) are routed to peroxisomes via the ER or a pre-peroxisomal
compartment, presumably by vesicular transport. A retrograde peroxi-
some-to-ER transport might exist. A novel vesicular mitochondria-to-
peroxisome traYcking route has been described recently (Neuspiel
et al. 2008), but its function is still mysterious. It is currently unknown,
whether a retrograde peroxisome-to-mitochondrium transport exists,
and whether peroxisome-derived vesicles contribute to the removal of
damaged (e.g., by ROS production), misfolded or mistargeted proteins.
Besides ER and mitochondria (Mito), peroxisomes are supposed to
interact with the smooth ER (sER), with lipid droplets/bodies, the
cytoskeleon, and other peroxisomes (Schrader et al. 2000). Peroxi-
somes can multiply by growth/elongation, constriction and Wnal
Wssion/division, forming spherical peroxisomes. Pex11p is involved
in the elongation/tubulation of peroxisomes, whereas DLP1/Drp1 and
Fis1p mediate peroxisomal Wssion (Schrader and Fahimi 2006). Fis1p
is supposed to recruit cytosolic DLP1/Drp1 to the peroxisomal mem-
brane. The involvement of other proteins (related to yeast Mdv1p/
Caf4p) is likely. Components involved in the constriction of peroxi-
somes are presently unknown. Proper intracellular distribution of the
peroxisomes formed by Wssion requires microtubules (MT) and motor
proteins. In yeast and plants peroxisomes are distributed via the actin
cytoskeleton. The consecutive steps are linked to each other, and may
be triggered by the assembly of distinct machineries at the peroxisomal
membraneHistochem Cell Biol (2008) 129:421–440 429
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contribute to peroxisome numbers in yeast, Motley and
Hettema (2007) have developed an elegant, Xuorescence-
based mating assay to follow the fate of existing and de novo-
formed peroxisomes in S. cerevisiae. They provide evidence
that in wild-type cells (grown on a nonfermentable carbon
source) peroxisomes multiply by growth and division and do
not form de novo. Only cells lacking peroxisomes as a result
of a segregation defect were observed to form peroxisomes
de novo out of the ER. In contrast to peroxisome Wssion, de
novo formation was much slower and appeared to be inde-
pendent of DLPs such as Dnm1p or Vps1p (Motley and Het-
tema  2007; Nagotu et al. 2007; Jourdain et al. 2008). In
some yeasts, which possess only a few peroxisomes, de
novo formation may therefore represent a rescue mechanism
that becomes functional in case peroxisomes are lost (e.g.,
due to failure in inheritance). Several components involved
in peroxisome inheritance in yeast have recently been dis-
covered, for example the peroxisomal proteins Inp1p and
Inp2p, which together with the type V myosin motor Myo2p
and actin play a role in the retention and motility of peroxi-
somes (Fagarasanu et al. 2006, 2007) (Fig. 3).
However, there is now also Wrm evidence that some per-
oxisomal proteins are routed indirectly to peroxisomes via
the ER (e.g. Pex3p) (Hoepfner et al. 2005; Tam et al. 2005;
Kragt et al. 2005a; Haan et al. 2006; Kim et al. 2006; Mullen
and Trelease 2006; Motley and Hettema 2007). This traYck-
ing pathway is supposed to involve ER-derived vesicular or
preperoxisomal structures, which do not require DLPs for
exit from the ER (Motley and Hettema 2007; Nagotu et al.
2007), and are observed to fuse with pre-existing peroxi-
somes. Thus, a semi-autonomous model of peroxisome for-
mation can be envisaged, whereby the ER supplies existing
peroxisomes with essential membrane proteins (and lipids) to
allow peroxisomal growth and division (Fig. 5). However, it
is currently not understood how the peroxisomal proteins
enter and leave the ER, how they are sorted and packaged,
what the nature and composition of the ER-derived structures
is, how fusion with peroxisomes is mediated, and if a retro-
grade, peroxisome-to-ER pathway exists (Fig. 5). Interest-
ingly, such a retrograde transport pathway has recently been
proposed in infected plant cells (McCartney et al. 2005; Mul-
len and Trelease 2006) and trypanosomes (Subramanya and
Mensa-Wilmot  2006). Furthermore, a role of the Dsl1p
secretory complex in regulating de novo synthesis of peroxi-
somes from the ER has been very recently proposed in
S. cerevisiae (Perry and Rachubinski 2007).
Mysterious traYcking: a novel vesicular 
mitochondria-to-peroxisome pathway?
Besides vesicular ER-to peroxisome transport, even a trans-
port route between mitochondria and peroxisomes might
exist (Fig. 5). Neuspiel et al. (2008) have very recently iden-
tiWed a new outer membrane mitochondrial anchored protein
ligase (MAPL) containing a RING Wnger domain. MAPL
appeared to have a regulatory function in controlling mito-
chondrial morphology. Excitingly, MAPL was also incorpo-
rated within unique, vesicular structures, which emanated
from the sides of mitochondria. These new mitochondrial-
derived vesicles (MDVs) (70–100 nm in diameter) formed in
a DLP1-independent manner, showed an increase in electron
density around the surface, and often contained both outer
and inner mitochondrial membranes, which appeared as two
concentric circles. Remarkably, in live-cell experiments
MAPL-YFP-positive vesicles were observed to fuse with a
small subset of peroxisomes (Neuspiel et al. 2008). Further-
more, other populations of MDVs were discovered, which
excluded MAPL, but contained TOM20 (which was absent
form MAPL-positive MDVs). The TOM20-positive MDVs
did not fuse with peroxisomes, and their fate is still under
investigation. However, it might be possible that these vesi-
cles contribute to the removal of damaged, misfolded, or
mistargeted proteins from the mitochondria/mitochondrial
membranes, and route them to the lysosomal/autophagic deg-
radation pathway (Fig. 5). The physiological function of the
new vesicular mitochondria-to-peroxisome transport path-
way is also still mysterious. MAPL appears to be present at
low levels in only a subpopulation of peroxisomes, and is not
required for MDV formation at the mitochondria or targeting
to peroxisomes. Silencing or overexpression of MAPL was
not observed to change peroxisomal morphology, and thus, it
might not play a role in peroxisomal growth and division (in
contrast to its function on mitochondria). Peroxisomes and
mitochondria are metabolically linked organelles, which
cross talk and cooperate, and even share components of their
division machinery (Schrader 2006; Schrader and Yoon
2007) (Figs. 1, 4). The MAPL-positive MDVs might there-
fore function in the transport of metabolites, lipids, or pro-
teins to a peroxisome subpopulation. Interestingly, a dual
localization to both peroxisomes and mitochondria has been
observed for mitochondrial enzymes and some mitochondrial
membrane proteins (e.g., Fis1p, Mosc2, and ATAD1, a
member of the AAA-superfamily of ATPases) (Koch et al.
2005; Wiese et al. 2007) (see “Peroxisomes and mass spec-
trometry”). However, Fis1p and the other proteins are found
in the vast majority of peroxisomes (distinct from MAPL),
and are presumably imported directly from the cytosol. An
alternative function of the peroxisome-targeted MDVs might
be the retrieval of peroxisomal (membrane) proteins, which
have been mistargeted to mitochondria. Mistargeting of per-
oxisomal membrane proteins to mitochondria is often
observed under diVerent experimental conditions, for exam-
ple when peroxisomal membrane insertion is aVected (Sack-
steder et al. 2000; Soukupova et al. 1999), and might be due
to some overlap in the targeting information that is also
recognized by the mitochondrial import machinery (Van Ael430 Histochem Cell Biol (2008) 129:421–440
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and Fransen 2006; Subramani 1998). Another interesting
issue is the fusion event of a double-membrane-bound MDV
with a single-membrane-bound peroxisome (Neuspiel et al.
2008). Such a fusion would likely result in the release of a
single-membrane-bound vesicle (the former inner mitochon-
drial membrane) into the lumen of the peroxisome. Internal
peroxisomal membrane structures have been described in
yeast cells and in mammalian tissue (McNew and Goodman
1996), and very recently after deletion of the peroxisomal
lipase Lpx1p in S. cerevisiae (Thoms et al. 2008). It will be
very interesting to elucidate the fate of the putative vesicle
remnant, and to identify the components of the putative
MDV-peroxisome fusion machinery.
It is intriguing to speculate that peroxisomes them-
selves—like mitochondria—might be able to emenate vesi-
cles from their membranes (which would then be PDVs,
peroxisome-derived-vesicles) (Fig. 5). Budding events at the
peroxisomal membrane have been occasionally observed
(Jedd and Chua 2002). Furthermore, ADP-ribosylation fac-
tor (ARF) and coatomer have been localized to peroxisomes
(Passreiter et al. 1998; Lay et al. 2005). EVorts to link ARF
and coatomer recruitment to (ER-derived) peroxisome for-
mation or growth and division have so far been inconclusive
or are diYcult to interpret (Lay et al. 2006). It might actually
be possible that these components play only a minor, if any,
role in peroxisome formation, but are instead involved in the
generation of PDVs, which might either deliver metabolites,
lipids, or (mistargeted) proteins to mitochondria (or to other
subcellular compartments, e.g., to the ER; see “Mysterious
formation: growth and division, de novo formation, or
both?”), or might be involved in the removal of damaged
(e.g., by peroxisomal ROS production), misfolded, or
mistargeted (mitochondrial?) proteins from the peroxisomal
membranes, and route them to the lysosomal/autophagic
degradation pathway (Fig. 5). As the peroxisome appears to
be connected to transport pathways coming from the ER and
presumably also from mitochondria, there will certainly be
some degree of mistargeting. Therefore, mechanisms must
exist, which assist the peroxisome in getting rid of poten-
tially mistargeted proteins, especially those in the peroxi-
somal membrane, which are not readily accessible to
peroxisomal enzymes/proteases (e.g., membrane proteins
mainly exposed to the cytoplasm). Besides vesicle forma-
tion, these mechanisms might also include polyubiquitina-
tion (Platta and Erdmann 2007a) or autophagy/pexophagy of
the whole organelle (Sakai et al. 2006) (see below).
Mysterious removal: degradation and autophagy 
of peroxisomes
The number of peroxisomes in cells and their enzymatic
equipment is modiWed depending on metabolic state and
the environmental requirements. A well-known characteris-
tic of peroxisomes is their inducibility by divergent chemi-
cals and drugs which is mediated by the transcription
factors referred to as “peroxisome proliferator activated
receptors” (PPARs) (Issemann and Green 1990). Upon
withdrawal of treatment, the peroxisome proliferation is
reversed and the excess particles are removed by autophagy
(Yokota 1993) (Fig. 2e), which in the case of yeast cells is
also referred to as pexophagy (Sakai et al. 2006). Autoph-
agy is a process regulated by ATG genes, which determine
the sequestration and degradation of cell organelles and
other cellular components within lysosomes or vacuoles.
Two distinct mechanisms of sequestration by autophagy
have been described: macroautophagy and microautoph-
agy. Whereas in macroautophagy the cell components (e.g.,
peroxisomes) are Wrst sequestered within autophagosomes,
which in turn fuse with lysosomes/vacuoles, in
microautophagy membrane events occur on the surface of
the vacuole/lysosome which then engulf the cell compo-
nents to be digested resulting in the formation of micro-
autohagic bodies (Sakai et al. 1998a). From the numerous
ATG genes (Klionsky et al. 2003) involved in general cel-
lular autophagy, many have also been identiWed to partici-
pate in pexophagy (Schroder et al. 2007). On the other
hand, much less is known about the peroxisomal compo-
nents, which are involved in this process. In the yeast Han-
senula polymorpha two peroxisomal membrane proteins,
HpPex3p (Bellu et al. 2002) and HpPex14p (Bellu et al.
2001), appear to be important in the process of macropexo-
phagy. In yeasts lacking HpPex14p, degradation of peroxi-
somal membranes is defective and it is suggested that the
highly conserved N-terminal region of HpPex14p is neces-
sary for macropexophagy. Since Pex14p has also been
known to be a translocon and is involved in the formation
of peroxisomes (Fig. 3), it is the only Pex protein that par-
ticipates both in peroxisome formation and degradation
(Zutphen et al. 2008). The yeast models Pichia pastoris and
H. polymorpha have extensively been used for the analysis
of molecular events and the morphological steps of pexo-
phagy, and there are excellent recent reviews on this subject
(e.g., Dunn et al. 2005; Sakai et al. 1998b, 2006; Platta and
Erdmann 2007a).
In mammalian hepatocytes, the degradation of peroxi-
somes by autophagy was noted quite early by electron
microscopic studies in rodents treated with hypolipidemic
drugs (Leighton et al. 1975; Moody and Reddy 1976; Stau-
bli et al. 1977) (Fig. 2e). Although the morphological
aspects and the participation of lysosomes in this process
were well characterized (Yokota 2003), its molecular
aspects remained quite mysterious compared to yeast cells.
Recently, Iwata et al. (2006) reported that in Atg7-deWcient
mice (lacking the essential gene for autophagy), the excess
peroxisomes induced by phthalate ester could not beHistochem Cell Biol (2008) 129:421–440 431
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degraded within 1 week after discontinuation of the treat-
ment. Moreover, the Atg7-deWcient hepatocytes lacked the
autophagosomes containing sequestered peroxisomes, thus
conWrming the role of autophagy in degradation of excess
peroxisomes. Further studies are required to analyse the
role of other genes and their products in autophagy in mam-
malian systems and the search has just started (Monas-
tyrska and Klionsky 2006).
In addition to the autophagic degradation of excess per-
oxisomes discussed above, another unique aspect of turn-
over of this organelle deserves to be mentioned, namely,
the possible role of 15-lipoxygenase in selective destruction
of peroxisomal membranes in normal untreated animals. In
reticulocytes, 15-lipoxygenase has been shown to bind
selectively to the membranes of organelles and induce the
diVusion of their contents (van Leyen et al. 1998). The
importance of this process for the degradation of cell
organelles in diVerentiating lens Wbres (Bassnett and
Mataic 1997) and in maturation of reticulocytes has been
suggested (Schewe et al. 1975). This notion has been con-
Wrmed recently in Atg5¡/¡ mice which show normal orga-
nelle degradation in lens Wbres and erythroid cells inspite of
inability to form autophagic vacuoles (Matsui et al. 2006).
The presence of 15-lipoxygenase in the membranes of nor-
mal rat hepatocyte peroxisomes was demonstrated recently,
and it was suggested that, similar to maturing reticulocytes
and lens Wbres, it could also be involved in the degradation
of peroxisome membranes (Yokota et al. 2001). This notion
is supported by the observation that 15-lipoxygenase was
detected in only some but not all peroxisomes and that its
presence correlated with the diVusion of catalase from
some but not all peroxisomes in aldehyde Wxed sections of
rat liver. The latter Wnding was reported almost 30 years
before and was contributed to the heterogeneous stability of
peroxisome membranes (Fahimi 1974). Since the disrup-
tion of peroxisome membranes and the diVusion of catalase
were both prevented by inhibitors of 15-lipoxygenase such
as propyl gallate and esculetin, it was suggested that
15-lipoxygenase could participate in physiological degra-
dation and turnover of peroxisomes in normal untreated
animals, contrasting the role of autophagy in degradation of
excess peroxisomes induced by treatment with chemicals
and drugs (Yokota et al. 2001).
Mysterious protection: some recent observations 
on the relevance of peroxisomes in medicine
There are by now more than two dozens inborn metabolic
disorders due to various dysfunctions or absence of peroxi-
somes and that number is growing (Schluter et al. 2007).
Table 1 summarizes those disease conditions with the age
of the onset, the basic metabolic defect and the genes
involved. In addition to those genetic peroxisomal disor-
ders, which have been addressed in recent excellent reviews
(Weller et al. 2003; Wanders and Waterham 2005, 2006a;
Faust et al. 2005; Steinberg et al. 2006), there is also
increasing evidence that peroxisomes may be aVected in
some medical conditions associated with disorders of the
lipid metabolism. Since peroxisomes and their proteins can
be induced by a variety of drugs and chemicals, generally
referred to as PPAR-agonists, there are emerging new pos-
sibilities for therapy of those conditions. Two such disor-
ders are brieXy discussed here: fatty liver disease and
neuroinXammation.
Peroxisomes in fatty liver disease
The fatty liver disease (FLD) represents an excess accumu-
lation of triglycerides in hepatic parenchymal cells.
Whereas in the past excess ethanol consumption accounted
for most cases, which were called alcoholic FLD (AFLD),
in the last two decades, the non-alcoholic FLD (NAFLD),
particularly in association with obesity, has emerged as the
most common chronic liver condition in the western world
(Adams et al. 2005). NAFLD is now present in 17–33% of
the population in the United States, but has a world-wide
distribution, and parallels the frequency of central adipos-
ity, obesity, insulin resistance, metabolic syndrome and
type 2 diabetes (Farrell and Larter 2006). In almost one-
third of NAFLD cases, there is an associated steatohepatitis
(NASH), which progresses to hepatic Wbrosis and upon
chronicity to liver cirrhosis. Many cases of the so-called
cryptogenic liver cirrhosis are likely end-stage NASH
(Neuschwander-Tetri and Caldwell 2003). Although insulin
resistance is the underlying problem, in the pathogenesis of
FLD both excess energy consumption as well as defective
energy combustion contribute to a sequence of events
which begins with hepatic steatosis and ends in liver cirrho-
sis and cancer (Reddy and Rao 2006). Whereas hepatic ste-
atosis is considered to be innocuous and reversible, the
progression to steatohepatitis is inXuenced by the severity
and persistence of the causative agent and additional fac-
tors. According to the “two-hit” hypothesis, secondary
insults that may severely damage the steatotic liver include
reactive oxygen species, endotoxin, tumor necrosis factor-
alpha (TNF) and other cytokines (Day and James 1998).
In this respect, it should be noted that inXammatory cyto-
kines such as TNF have been shown to suppress the
hepatic peroxisomal catalase and the lipid -oxidation
enzymes, as well as the transcription factor PPAR, at both
protein and mRNA levels (Beier et al. 1992, 1997). The
reduction of the fatty acid -oxidation enzymes in peroxi-
somes could contribute to the lipid accumulation in hepato-
cytes and to the severity of steatohepatitis. Indeed, mice
lacking the peroxisomal acyl-CoA oxidase gene develop432 Histochem Cell Biol (2008) 129:421–440
123
severe steatohepatitis, lipogranulomas and hepatocellular
carcinomas (Fan et al. 1998). Some of the features of those
AOX¡/¡ mice resemble the spectrum of obesity associated
human liver alterations justifying further detailed studies of
peroxisomes in patients with morbid obesity and type 2 dia-
betes.
From the PPAR subfamily of nuclear transcription fac-
tors (Michalik et al. 2006), the PPAR functions mainly as
a lipid sensor in the liver responding to the inXux of fatty
acids by up-regulation of the transcription of genes
involved in -oxidation of fatty acids in peroxisomes and
mitochondria, as well as the microsomal -oxidation sys-
tem. PPAR¡/¡ mice cannot respond to increased fatty acid
inXux and develop severe hepatic steatosis (Hashimoto
et al. 2000). Such PPAR–/¡ mice also develop severe ste-
atohepatitis after feeding with a choline and methionine
deWcient diet (Kashireddy and Rao 2004). Interestingly,
both agonists of PPAR and PPAR have been found to
improve the hepatic steatosis and prevent the inXammation
associated with steatohepatitis induced by choline-methio-
nine deWcient diet in mice (Nagasawa et al. 2006). More
importantly, in rats with severe steatohepatitis and liver
Wbrosis induced by a choline-methionine deWcient diet,
administration of PPAR agonists prevents not only the
development of steatohepatitis but also reverses the Wbrotic
process in the liver (Rao et al. 2002). Thus, it seems that
induction of fatty acid oxidation enzymes by activation of
PPAR and PPAR can prevent the development of hepatic
steatosis. Indeed, in clinical studies, the PPAR agonists
rosiglitazone (Neuschwander-Tetri et al. 2003) and pioglit-
azone (Promrat et al. 2004) have been tried and found to
improve signiWcantly all histological and biochemical fea-
tures of non-alcoholic steatohepatitis. This has also been
proven in a placebo-controlled trial with pioglitazone justi-
fying further long-term studies (Belfort et al. 2006). Thus,
PPAR-agonists such as Wbrates or thiazolidinediones oVer
the potential for treatment of not only the hepatic complica-
tions but also the underlying disease process of metabolic
syndrome and type 2 diabetes with dyslipidaemia (Plutzky
2007; Staels 2007).
Peroxisomes and neuroinXammatory diseases
The severe structural and functional abnormalities of the
central nervous system (CNS) seen in patients with peroxi-
some biogenesis disorders (PBDs) (Evrard et al. 1978;
Powers et al. 1985) (Table 1) demonstrate the important
role of peroxisomes in normal development and function of
the brain. This is also conWrmed in brain speciWc gene-
knock out mouse models of PEX5 (Janssen et al. 2003) and
PEX2 (Faust 2003), which exhibit neuronal migration
defects and abnormalities in cerebellar histogenesis, respec-
tively. Recently, in a mouse model of selective knock out of
PEX5 in oligodendrocytes, the central role of peroxisomes
in the myelination process was demonstrated (Kassmann
et al. 2007). Although the mutant mice appeared normal at
birth, within a few months they developed ataxia, tremor
and died prematurely with widespread evidence of axonal
degeneration and progressive subcortical demyelination.
Moreover, severe inXammation accompanied the axonal
degeneration with inWltration of B and CD8+ T cells in
cerebral lesions resembling closely the neuroinXammatory
lesions associated with human demyelinating disorders,
particularly the multiple sclerosis.
Thus, it seems that peroxisomes in oligodendrocytes
have a neuroprotective function preventing not only the
axonal degeneration but also the associated process of neur-
oinXammation. The anti-inXammatory function of peroxi-
somes and the regulatory role of PPAR-activators in this
process were discovered more than a decade ago (Devc-
hand et al. 1996). Both, PPAR and PPAR, are expressed
on T cells, and their respective agonists inhibit the secretion
of interleukin-2 and the proliferation of T cells (Cunard
et al. 2002; Marx et al. 2002). Moreover, PPAR-agonists
have been found to inhibit the progression of a variety of
inXammatory diseases in experimental animals such as
adjuvant arthritis in rats (Kawahito et al. 2000), inXamma-
tory bowel disease (Su et al. 1999) and atherosclerosis in
mice (Li et al. 2000). Experimental autoimmune encephalo-
myelitis (EAE) is an autoimmune disorder in mice charac-
terized by inXammation of the CNS and severe
demyelination which are the typical features of multiple
sclerosis in humans and both PPAR and PPAR agonists
have been shown to exert therapeutic eVects in the mouse
model (Niino et al. 2001; Diab et al. 2002; Xu et al. 2007).
Moreover, in a report of a single patient with severe multi-
ple sclerosis, pioglitazone, a PPAR activator, was found to
substantially improve the patients condition (Pershadsingh
et al. 2004). Those observations have now stimulated the
call for large-scale clinical trials of PPAR-agonists for ther-
apy of multiple sclerosis (Racke et al. 2006; Niino 2007).
Since an inXammatory process in the brain is also observed
in other severe conditions aVecting the CNS such as Alz-
heimer’s and Parkinson’s disease, PPAR-agonists have also
been tried (Landreth 2007; Dehmer et al. 2004) with prom-
ising results, thus justifying future trials of those drugs in
various neurological disorders associated with neuroinXam-
mation. It is of interest that not all eVects of those receptor-
agonists are mediated via the activation of PPAR, since
some therapeutic eVects are also observed with gemWbrozil,
a PPAR agonist, in PPAR¡/¡ mice with autoimmune
encephalomyelitis (Dasgupta et al. 2007) suggesting recep-
tor independent mechanisms of action. This is, however,
mostly new territory where therapeutic beneWts of those
drugs remain to be discovered. The exact knowledge of the
structure and function of peroxisomes and their heterogeneityHistochem Cell Biol (2008) 129:421–440 433
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in the CNS, as reported recently (Ahlemeyer et al. 2007) is
a prerequisite for such future studies.
Mysterious players: identifying novel peroxisomal 
proteins
Peroxisomes in silico
The rapid advances in genome sequencing allow computa-
tional approaches (comparative genomics) to predict perox-
isomal proteins. These in silico analyses take advantage of
the conserved targeting sequences in peroxisomal proteins
(i.e. PTS1, PTS2, see “Introduction” and Fig. 3). PTS
domain-based comparisons across genomes from yeast to
humans and plants have been performed, predicting large
numbers of putative peroxisomal proteins (Emanuelsson
et al.  2003; Kurochkin et al. 2005; Kamada et al. 2003;
Reumann et al. 2004, database AraPerox: http://www.ara-
perox.uni-goettingen.de/; Hawkins et al. 2007). Some of
the predictions have already been conWrmed experimen-
tally, others still await validation. There are, however, limi-
tations, because many proteins of peroxisomes cannot
currently be predicted from genome sequences. These
include peripheral and integral membrane proteins, proteins
that are imported in a piggy-back fashion, or matrix pro-
teins with internal PTS1-like peptides. On the other hand,
predicted PTSs can be masked by protein conformation,
multimer formation, or posttranslational regulatory mecha-
nisms.
Mysterious rise
Recently, computational approaches on the basis of proteo-
mes and sequenced genomes of diVerent organisms have
been used to investigate the evolutionary origin of peroxi-
somes (Schluter et al. 2006; Gabaldon et al. 2006; Schluter
et al.  2007, peroxisome database: http://www.peroxi-
somedb.org/). The peroxisomal proteins Pex3p, Pex19p,
Pex10p, and Pex12p have been identiWed as markers for
unequivocal in silico peroxisome detection (Schluter et al.
2006). The Apicomplexa phylum (containing for example,
Plasmodium falciparum, Cryptosporidium parvu) has been
detected as the Wrst group of organisms devoid of peroxi-
somes in the presence of mitochondria. The absence of
peroxisomes had so far only been documented in
amitochondriate parasites, such as Encephalitozoon cunic-
uli, Girardia lamblia, or Entamoeba histolytica. Interest-
ingly, a high degree of similarity among membrane
proteins and between components of the matrix import
machinery and the endoplasmic reticulum/proteasome deg-
radation system has been observed (see “Mysterious forma-
tion: growth and division, de novo formation, or both?”)
(Schluter et al. 2006; Gabaldon et al. 2006). Most of the
conserved peroxisome biogenesis and maintenance proteins
are apparently eukaryotic innovations with no prokaryotic
counterpart. This is consistent with Wndings that report an
ER-dependent formation of peroxisomes (see “Mysterious
formation: growth and division, de novo formation, or
both?”) (Tabak et al. 2006), and indicates that peroxisomes
do not have an endosymbiotic origin. In contrast, many per-
oxisomal matrix enzymes were found to have prokaryotic
homologues. These might have been recruited individually
from pools existing within the primitive eukaryote (e.g.,
from mitochondria), but an en bloc recruitment of this
coherent collection of enzymes can also be envisaged (de
Duve 2007). It is still an open (but interesting, and hotly
debated) question, when the peroxisomes Wrst appeared in
the evolution of the eukaryotic cell, and if they might have
been present before the adoption of mitochondria (Cava-
lier-Smith 1997).
Peroxisomes and mass spectrometry
The recent technical advances in two-dimensional gel elec-
trophoresis (2D-GEP), liquid chromatography (LC), as well
as mass spectrometrical (MS) peptide identiWcation and
quantiWcation laid the foundation for progress in organellar
proteome studies, and have also been exploited to unravel
the peroxisomal proteome. These studies depend not only
on the availability of complete genome information or large
EST collections of the species of interest for protein identi-
Wcation but also on the purity of the isolated organelle frac-
tion. Due to the fragile nature of peroxisomes, the isolation
of intact peroxisomes in high purity and suYcient quantity
is diYcult. However, sophisticated protocols have been
developed for the isolation of mammalian peroxisomes, for
fungi and yeast, as well as for plant peroxisomes (e.g.,
Völkl et al. 1996,  1999; Luers et al. 1998; Weber et al.
2004; Distel and Kragt 2006; Reumann et al. 2007).
One-dimensional (1D) and 2D-GEP of peroxisomes
from rat liver followed by LC/tandem MS or MS resulted in
the identiWcation of more than 50 known constituents as
well as novel peroxisomal proteins, among them a new iso-
form of Lon protease (one of the Wrst peroxisomal proteases
discovered) (Kikuchi et al. 2004), microsomal gluthatione-
S-transferase (Islinger et al. 2006), as well as the known
microsomal proteins aldehyde dehydrogense, cytochrome
b5 and its corresponding reductase (Kikuchi et al. 2004;
Islinger et al. 2006; Wiese et al. 2007). An early high
throughput characterization of the yeast peroxisomal mem-
brane proteome was performed by Schafer et al. (2001)
using oleate-induced cultures. In order to diVerentiate
between proteins that are contaminants of low abundance
and those that have speciWcally enriched in the puriWed per-
oxisome fractions, eVorts have been made to study relative434 Histochem Cell Biol (2008) 129:421–440
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protein quantities. Aitchinson and coworkers introduced a
relative quantitative MS-based proteomics approach
(ICAT, isotope-coded aYnity tagging) to determine the
enrichment or depletion of proteins detected in two peroxi-
somal membrane fractions from S. cerevisiae that diVered
in their degree of purity, and revealed a role for the GTPase
Rho1p in actin organization on the peroxisomal membrane
(Marelli et al. 2004; Saleem et al. 2006). In another quanti-
tative MS-based proteomics approach (iTRAQ, isobaric
Tag for Relative and Absolute Quantitation) with peroxi-
some matrix and membrane subfractions from bezaWbrate
treated rats, Islinger et al. (2007) identiWed 134 individual
proteins, including 15 new candidates, among them the new
peroxisomal membrane proteins PMP52 (unknown func-
tion, related to PMP24), the iron–sulfur protein Mosc2
(MOCO sulphurase C-terminal domain containing 2 pro-
tein), and splice variants of the acyl-CoA binding protein
ACBD5, as well as a trypsin-like serine protease (Tysnd1)
of the peroxisomal matrix (Fig. 3). The mouse variant of
this protease has been identiWed and characterized in detail
(Kurochkin et al. 2007). Interestingly, Tysnd1 removes the
leader peptide from PTS2 proteins and speciWcally pro-
cesses PTS1 proteins involved in peroxisomal -oxidation.
Proteomic characterization of mouse kidney peroxisomes
by tandem MS and protein correlation proWling has also led
to the identiWcation of 15 new peroxisomal candidates
including Zadh2 (Zinc-binding alcohol dehydrogensase
domain containing protein 2), Acad11 (acyl-CoA dehydro-
genase family member 11), the aforementioned ACBD5,
PMP52, Mosc2 (Wiese et al. 2007), as well as nudix hydro-
lase 19 (RP2) (Ofman et al. 2006). In addition, a quantita-
tive proteomic comparison of mouse peroxisomes from
liver and kidney has been performed (Mi et al. 2007b), as
well as an age-related subproteomic analysis (Mi et al.
2007a). With the development of a puriWcation method for
leaf peroxisomes, Reumann et al. (2007) were able to per-
form a comprehensive proteome analysis of Arabidopsis
leave peroxisomes. They identiWed 42 novel proteins that
had previously not been assigned to plant peroxisomes
revealing novel targeting peptides, metabolic pathways,
and defense mechanisms (Reumann et al. 2007). All these
studies have contributed to a more complete picture of the
peroxisome, and clearly demonstrate that we are not look-
ing at an isolated structure, but rather on a dynamic com-
partment that is linked to (and might interact with) other
subcellular structures (e.g. the ER, mitochondria, chloro-
plasts, the cytoskeleton, lipid droplets/bodies and other per-
oxisomes), and even shares proteins with them (in
particular with the ER and mitochondria).
Although mass spectrometry can generally be more
accurate than antibody-based detection methods, a valida-
tion of the proteins predicted to be peroxisomal is often
required. The peroxisomal localization of some of the iden-
tiWed novel proteins has been experimentally conWrmed by
expression studies with tagged proteins, and by antibody-
based approaches such as immunoXuorescence microscopy
and immunoblotting (e.g. Marelli et al. 2004; Islinger et al.
2006, 2007; Wiese et al. 2007).
In addition, large-scale localization studies have been
performed in which the whole genome or a subset of the
organisms’ proteome was systematically tagged with GFP.
The subcellular localizations of the GFP fusion proteins
and their dynamics can then be addressed under live cell
conditions, and several fusion proteins with peroxisomal
localization have been identiWed by this approach (Cutler
et al. 2000; Kumar et al. 2002; Huh et al. 2003; Natter et al.
2005).
Nevertheless, a lot of large-scale data are awaiting vali-
dation and contextualization. The great challenge for the
future will be to provide a comprehensive and more com-
plete picture of the relevant peroxisomal proteins, their
abundance, functions, interactions and dynamic changes
(Saleem et al. 2006). This can only be achieved by incorpo-
rating data from multiple sources, such as localization (see
above) and interaction studies (e.g., two hybrid studies,
analyses of immunoisolated protein complexes), metabolite
interactions, and microarray expression analyses.
Concluding remarks
This review has highlighted recent novel discoveries in the
peroxisome Weld. Ongoing studies on peroxisome biogene-
sis, formation and protein import have so far revealed
unique features of peroxisomes, which have often been in
disagreement with existing dogmas in cell biology. Con-
trary to mitochondria and ER, peroxisomal proteins can be
imported in a completely folded or even oligomeric state,
presumably via the formation of a transient membrane
pore (Erdmann and Schliebs 2005). Recent Wndings also
demonstrate that peroxisomes can be formed de novo from
the ER or a subdomain of the ER (Hoepfner et al. 2005) in
addition to growth and division of pre-existing peroxi-
somes (Yan et al. 2005; Schrader 2006; Fagarasanu et al.
2007). Furthermore, they appear to have an ER origin in
evolutionary history (Gabaldon et al. 2006; Schluter et al.
2006). The physiological signiWcance of the mechanism of
de novo formation in comparison to the classical pathway
of growth and division has again been challenged (Motley
and Hettema 2007) and awaits further approval. In contrast
to peroxisome division, de novo formation appears to be
independent of dynamin-like proteins (Motley and Het-
tema 2007; Nagotu et al. 2007) and thus, the molecular
machinery for de novo formation remains to be identiWed.
Many new proteins aVecting peroxisome growth, number,
division, inheritance and turnover have been characterizedHistochem Cell Biol (2008) 129:421–440 435
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and much has been learned about their putative function,
localization, and possible interaction with other proteins.
The discovery that dynamin-related proteins like Vps1,
DLP1/Drp1 and DLP/Drp-receptor proteins like Fis1p are
required for peroxisomal Wssion has opened the Weld for
the molecular characterization of the peroxisomal division
machinery (Schrader and Fahimi 2006). Interestingly, per-
oxisomes and mitochondria share components of their
Wssion machinery, underlining the tight cooperation and
cross talk between both organelles (Schrader 2006; Sch-
rader and Yoon 2007). It is still an open question, how the
dual targeting of these components is mediated, and if
organelle-speciWc components exist which distinctly regu-
late the assembly of the division machineries on both
organelles. Furthermore, the mechanism of peroxisome
constriction and of membrane phospholipid transfer during
growth or de novo synthesis remains to be discovered.
Another important question is, if and how peroxisomal
morphology and dynamics inXuence peroxisomal func-
tions as well as developmental and physiological pro-
cesses. An improved understanding of the signalling
pathways and the PPAR-mediated mechanism of peroxi-
some proliferation will further stimulate the investigation
of the risks and beneWts of peroxisome proliferators as
therapeutical agents, for example in fatty liver disease or
neuroinXammatory diseases.
There is Wrm evidence now for a semi-autonomous
model of peroxisome formation, whereby the ER supplies
existing peroxisomes with essential membrane proteins to
allow growth and division. It will be a great challenge for
the future to elucidate this traYcking pathway, which is
supposed to involve ER-derived vesicular or pre-peroxi-
somal structures. Surprisingly, besides vesicular ER-to per-
oxisome transport, even a vesicular transport route between
mitochondria and peroxisomes might exist (Neuspiel et al.
2008). It will therefore be of signiWcant interest to unravel
to what extend, why and how peroxisomes interact and
exchange with other subcellular compartments, and
whether they are themselves involved in the formation of
vesicles. It is clear now that we are not looking at an iso-
lated structure, but rather on a dynamic compartment that is
linked to other subcellular structures, interacts with them
and even shares proteins. There is no doubt that peroxi-
somes, which are still among the more mysterious subcellu-
lar compartments in eukaryotic cells, will reveal further
surprises in the near future.
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